Bagherzadeh-Fard Mahsa, Amin Yazdanifar Mohammad, Sadeghalvad Mona, Rezaei Nima
Qom University of Medical Sciences, Qom, Iran; Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Systematic Review and Meta-Analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Int Immunopharmacol. 2023 Apr;117:109366. doi: 10.1016/j.intimp.2022.109366. Epub 2023 Mar 9.
This systematic review aims to show the efficiency of Erenumab in the preventive therapy of episodic and chronic migraine, which is still under research.
Migraine is a chronic neurovascular disorder that causes disability and a social burden. There are various medications used for migraine prevention regimens, most of which have unwanted side effects and aren't often quite effective. Erenumab is a monoclonal antibody that targets calcitonin gene-related peptide receptors and was recently approved by the Food and Drug Administration for migraine prevention.
For this systematic review, we searched through Scopus and PubMed databases using "Erenumab" or "AMG 334" and "migraine" as keywords, and all the studies from 2016 to March 18, 2022, were included. Original English articles assessing any outcomes referring to the efficacy of Erenumab in migraine headache treatment were included in this study.
We found 53 out of 605 papers eligible to be investigated. Erenumab in both dosages of 70 mg and 140 mg could decrease the mean of monthly migraine days and monthly acute migraine-specific medication days. Erenumab also has a higher rate of ≥ 50 %, ≥ 75 %, and 100 % reduction in monthly migraine days from the baseline in different regions. The efficacy of Erenumab was initiated in the first week of administration and sustained throughout and after treatment. Erenumab was also potent in the treatment of migraine with allodynia, aura, prior preventive therapy failure, medication overuse headache, and menstrual migraine. Erenumab also had favorable outcomes in combination therapy with other preventive drugs like Onabotulinumtoxin-A.
Erenumab had remarkable efficacy in the short and long-term treatment of episodic and chronic migraine, notably the patients with difficult-to-treat migraine headaches.
本系统评价旨在展示erenumab在发作性和慢性偏头痛预防性治疗中的有效性，该治疗仍在研究中。
偏头痛是一种慢性神经血管疾病，会导致残疾和社会负担。用于偏头痛预防方案的药物有多种，其中大多数有不良副作用且效果往往不太理想。Erenumab是一种靶向降钙素基因相关肽受体的单克隆抗体，最近被美国食品药品监督管理局批准用于偏头痛预防。
对于本系统评价，我们在Scopus和PubMed数据库中以“erenumab”或“AMG 334”以及“偏头痛”作为关键词进行检索，纳入了2016年至2022年3月18日的所有研究。本研究纳入了评估erenumab在偏头痛治疗有效性的任何结果的英文原文。
我们在605篇论文中发现53篇符合调查条件。70mg和140mg两种剂量的erenumab均可减少每月偏头痛天数和每月急性偏头痛特异性用药天数的平均值。在不同地区，erenumab使每月偏头痛天数较基线减少≥50%、≥75%和100%的比例也更高。Erenumab的疗效在给药第一周开始显现，并在治疗期间及治疗后持续存在。Erenumab在治疗伴有痛觉过敏、先兆、既往预防性治疗失败、药物过度使用性头痛和月经性偏头痛的偏头痛方面也很有效。Erenumab与其他预防性药物如A型肉毒毒素联合治疗时也有良好效果。
Erenumab在发作性和慢性偏头痛的短期和长期治疗中具有显著疗效，尤其是对难治性偏头痛患者。
